Results 121 to 130 of about 110,732 (262)

Fast Quantitative Evaluation of the Amelioration Effect in MASLD During Semaglutide Treatment Using Ultrasound‐Derived Fat Fraction and Fat‐to‐Muscle Ratio

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a chronic liver disease. Research into a feasible, rapid, and effective assessment method is crucial for evaluating the therapeutic effects of semaglutide in MASLD. This prospective study utilized ultrasound‐derived fat fraction measurement and fat‐to‐muscle ratio to evaluate hepatic ...
Yunlin Huang, Ruping Yang, Ying Wang, Xiu‐Yun Lu, Li Wei, Rui Cheng, Juan Cheng, Yijie Qiu, Shiwen Wang, Bo Li, Yi Dong   +10 more
wiley   +1 more source

Hepatitis E Virus Infection in Patients With Chronic Liver Diseases: A Latin American Multicenter Study. [PDF]

J Infect Dis
Fantilli AC, Pisano MB, Martínez Wassaf M, Di Cola G, Balderramo D, Romagnoli P, Prieto J, Arrese M, Carrera E, Díaz Ferrer J, Mattos AZ, Fernández M, Britos GM, Bernaschini ME, Sepúlveda SA, Roa JC, Grutadauria S, Zerega A, Ferreiro M, González Ballerga E, Salmon J, Boonstra A, Debes JD, Ré VE.   +23 more
europepmc   +1 more source

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

Laparoscopic Cholecystectomy for Ruptured Gallbladder Varices Diagnosed by Preoperative Endoscopic Ultrasonography: A Case Report. [PDF]

Surg Case Rep
Hirano T, Nishihara M, Honda M, Asano S, Ozawa N, Himeiwa S, Iida H, Terada S, Kawamitsu H.   +8 more
europepmc   +1 more source

The Dynamic Evolution of Lipid Profiles Following Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
Cirrhosis is frequently accompanied by varying degrees of lipid profile abnormalities. This study confirms that these profiles are differentially affected by disease etiology and progressively worsen—with significant reductions in TC, HDL‐C, and LDL‐C—as liver disease severity increases. TIPS improves lipid profiles, particularly by increasing HDL‐C in
Jiamin Xu, Qinnian Li, Lagan Kumar Manandhar, Bilian Zhu, Chenrui Zhang, Weimin Bao, Yingmei Tang   +6 more
wiley   +1 more source

Multimorbidity patterns and their associations with healthcare services utilisation in inpatients with chronic hepatitis B infection from 2011 to 2023: a retrospective observational study. [PDF]

BMJ Open
Wang X, Xie J, Wu Y, Chen G, Ao H, Liu Z, Jie Y, Gu J.   +7 more
europepmc   +1 more source

Chinese Registry on Transjugular Intrahepatic Portosystemic Shunts (CN‐TIPS): Protocol for a Registry‐Based, Prospective Prognostic Study

Portal Hypertension &Cirrhosis, EarlyView.
CN‐TIPS is a nationwide, multicenter prospective registry that will enroll 10,000 adults with portal hypertension undergoing transjugular intrahepatic portosystemic shunt in China, integrating perioperative clinical and hemodynamic metrics with standardized imaging (including computational modeling in a dedicated subcohort) and multi‐omics biospecimens,
Yi Xiang, Yong Lv, Hongwei Zhou, Jianbo Zhao, Meng Niu, Jiacheng Liu, Guangchuan Wang, Qi Zhang, Weizhong Zhou, Beijia Yu, Jun Chi, Guo Han, Jiawei Zhang, Long Gao, Wenjing Liu, Zhang Zhang, Tianyu Liu, Wuhua Guo, He Zhao, Gao‐Jun Teng, Xiaolong Qi   +20 more
wiley   +1 more source

Dynamic immune landscape of NAFLD highlights pDCs as predictive biomarkers for disease progression. [PDF]

Front Immunol
Huang G, Xing S, Long Z, Gao W, Kuang S, Liu M, Zou Y, Zhuo C, Dong X.   +8 more
europepmc   +1 more source

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Portal Hypertension &Cirrhosis, EarlyView.
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang, Zhenyu Liu, Jun Lin, Weijing Zhang, Xianzhi Liu, Tong Zhang   +5 more
wiley   +1 more source

Alcohol Abstinence Is Associated with Regression of Non-Invasive Fibrosis Markers in Patients with Metabolic Syndrome: A 12-Month Prospective Study. [PDF]

J Clin Med
Mihăilă D, Domnariu HP, Moga DF, Domnariu CD.   +3 more
europepmc   +1 more source